simcyp simulator Search Results


pbpk simulator simcyp v18  (Simcyp)
90
Simcyp pbpk simulator simcyp v18
Pbpk Simulator Simcyp V18, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbpk simulator simcyp v18/product/Simcyp
Average 90 stars, based on 1 article reviews
pbpk simulator simcyp v18 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cyp3a4 ontogeny profile in the simcyp simulator  (Simcyp)
90
Simcyp cyp3a4 ontogeny profile in the simcyp simulator
Cyp3a4 Ontogeny Profile In The Simcyp Simulator, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyp3a4 ontogeny profile in the simcyp simulator/product/Simcyp
Average 90 stars, based on 1 article reviews
cyp3a4 ontogeny profile in the simcyp simulator - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
paediatric module in simcyp simulator® v18  (Simcyp)
90
Simcyp paediatric module in simcyp simulator® v18
Paediatric Module In Simcyp Simulator® V18, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/paediatric module in simcyp simulator® v18/product/Simcyp
Average 90 stars, based on 1 article reviews
paediatric module in simcyp simulator® v18 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
simulator v22  (Simcyp)
90
Simcyp simulator v22
Simulator V22, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/simulator v22/product/Simcyp
Average 90 stars, based on 1 article reviews
simulator v22 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
simcyp simulator libraries  (Simcyp)
90
Simcyp simcyp simulator libraries
Simcyp Simulator Libraries, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/simcyp simulator libraries/product/Simcyp
Average 90 stars, based on 1 article reviews
simcyp simulator libraries - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pediatric platform version 14  (Simcyp)
90
Simcyp pediatric platform version 14
Pediatric Platform Version 14, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pediatric platform version 14/product/Simcyp
Average 90 stars, based on 1 article reviews
pediatric platform version 14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
population-based adme simulator  (Simcyp)
90
Simcyp population-based adme simulator
Population Based Adme Simulator, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/population-based adme simulator/product/Simcyp
Average 90 stars, based on 1 article reviews
population-based adme simulator - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
simulator version 13, release 2  (Simcyp)
90
Simcyp simulator version 13, release 2
Simulator Version 13, Release 2, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/simulator version 13, release 2/product/Simcyp
Average 90 stars, based on 1 article reviews
simulator version 13, release 2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
computer-based simulation  (Simcyp)
90
Simcyp computer-based simulation
Time-course of <t>erlotinib</t> depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.
Computer Based Simulation, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/computer-based simulation/product/Simcyp
Average 90 stars, based on 1 article reviews
computer-based simulation - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
simulated kinetics  (Simcyp)
90
Simcyp simulated kinetics
Time-course of <t>erlotinib</t> depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.
Simulated Kinetics, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/simulated kinetics/product/Simcyp
Average 90 stars, based on 1 article reviews
simulated kinetics - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
simulator default compound library  (Simcyp)
90
Simcyp simulator default compound library
Time-course of <t>erlotinib</t> depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.
Simulator Default Compound Library, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/simulator default compound library/product/Simcyp
Average 90 stars, based on 1 article reviews
simulator default compound library - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
simulator v19  (Simcyp)
90
Simcyp simulator v19
Time-course of <t>erlotinib</t> depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.
Simulator V19, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/simulator v19/product/Simcyp
Average 90 stars, based on 1 article reviews
simulator v19 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Time-course of erlotinib depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Time-course of erlotinib depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Standard Deviation

Area under the concentration-time curve for erlotinib depletion and desmethyl erlotinib formation in primary cultures of human hepatocytes treated with vehicle (DMSO), ritonavir, or ketoconazole and incubated with erlotinib (5 μ M)

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Area under the concentration-time curve for erlotinib depletion and desmethyl erlotinib formation in primary cultures of human hepatocytes treated with vehicle (DMSO), ritonavir, or ketoconazole and incubated with erlotinib (5 μ M)

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Concentration Assay, Incubation

Half-life ( t 1/2 ), % erlotinib metabolized after 48 hours, M/P to AUC ratio, T max of desmethyl erlotinib, and apparent intrinsic clearance (CL int, app ) of erlotinib in primary cultures of human hepatocytes treated with vehicle (DMSO), ritonavir, or ketoconazole and incubated with erlotinib (5 μ M)

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Half-life ( t 1/2 ), % erlotinib metabolized after 48 hours, M/P to AUC ratio, T max of desmethyl erlotinib, and apparent intrinsic clearance (CL int, app ) of erlotinib in primary cultures of human hepatocytes treated with vehicle (DMSO), ritonavir, or ketoconazole and incubated with erlotinib (5 μ M)

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Incubation

Time-course of erlotinib depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), efavirenz (●), or rifampin (□). Data are representative of three individual experiments each performed in duplicate. Error bars represent standard deviation.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Time-course of erlotinib depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), efavirenz (●), or rifampin (□). Data are representative of three individual experiments each performed in duplicate. Error bars represent standard deviation.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Standard Deviation

Area under the concentration-time curve for erlotinib depletion and desmethyl erlotinib formation in primary cultures of human hepatocytes treated with vehicle (DMSO), efavirenz, or rifampin and incubated with erlotinib (5 μ M)

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Area under the concentration-time curve for erlotinib depletion and desmethyl erlotinib formation in primary cultures of human hepatocytes treated with vehicle (DMSO), efavirenz, or rifampin and incubated with erlotinib (5 μ M)

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Concentration Assay, Incubation

Half-life ( t 1/2 ), % erlotinib metabolized after 8 and 24 hours, M/P to AUC ratio, T max of desmethyl erlotinib, and apparent intrinsic clearance (CL int, app ) of erlotinib in primary cultures of human hepatocytes treated with vehicle (DMSO), efavirenz, or rifampin and incubated with erlotinib (5 μ M)

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Half-life ( t 1/2 ), % erlotinib metabolized after 8 and 24 hours, M/P to AUC ratio, T max of desmethyl erlotinib, and apparent intrinsic clearance (CL int, app ) of erlotinib in primary cultures of human hepatocytes treated with vehicle (DMSO), efavirenz, or rifampin and incubated with erlotinib (5 μ M)

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Incubation

Predicted human hepatic or oral clearance (CLhep or CLoral) of erlotinib from primary cultures of human hepatocytes treated with DMSO, ritonavir, or ketoconazole. *P < 0.05 versus DMSO; nonparametric Friedman analysis of variance followed by Dunn’s multiple comparison test.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Predicted human hepatic or oral clearance (CLhep or CLoral) of erlotinib from primary cultures of human hepatocytes treated with DMSO, ritonavir, or ketoconazole. *P < 0.05 versus DMSO; nonparametric Friedman analysis of variance followed by Dunn’s multiple comparison test.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Comparison

Predicted human hepatic or oral clearance (CLhep or CLoral) of erlotinib from primary cultures of human hepatocytes treated with DMSO, efavirenz, or rifampin. *P < 0.05 versus DMSO; nonparametric Friedman analysis of variance followed by Dunn’s multiple comparison test.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Predicted human hepatic or oral clearance (CLhep or CLoral) of erlotinib from primary cultures of human hepatocytes treated with DMSO, efavirenz, or rifampin. *P < 0.05 versus DMSO; nonparametric Friedman analysis of variance followed by Dunn’s multiple comparison test.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Comparison

The parameters used for the prediction of hepatic clearance and the comparisons of observed and predicted CL oral values for erlotinib with prediction errors Observed CL oral values (1.9, 3.3, 1.1, 5.3, 5.75, 4.08) were obtained from literature ( N = 6) ( Messersmith et al., 2004 ; Miller et al., 2007 ; Rudin et al., 2008 ; van Erp et al., 2009 ; Padda et al., 2012 ). Predicted CL oral values (0.853, 0.696, 0.997, 0.793, 0.651, 0.668) were obtained from six different vehicle-treated human hepatocytes.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: The parameters used for the prediction of hepatic clearance and the comparisons of observed and predicted CL oral values for erlotinib with prediction errors Observed CL oral values (1.9, 3.3, 1.1, 5.3, 5.75, 4.08) were obtained from literature ( N = 6) ( Messersmith et al., 2004 ; Miller et al., 2007 ; Rudin et al., 2008 ; van Erp et al., 2009 ; Padda et al., 2012 ). Predicted CL oral values (0.853, 0.696, 0.997, 0.793, 0.651, 0.668) were obtained from six different vehicle-treated human hepatocytes.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques:

Recovery of ritonavir-mediated inhibition (top) and efavirenz-mediated induction (bottom) of erlotinib metabolism in primary cultures of human hepatocytes. Data are representative of three individual experiments each performed in duplicate. Error bars represent standard deviation.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Recovery of ritonavir-mediated inhibition (top) and efavirenz-mediated induction (bottom) of erlotinib metabolism in primary cultures of human hepatocytes. Data are representative of three individual experiments each performed in duplicate. Error bars represent standard deviation.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Inhibition, Standard Deviation